source
- Celcuity waits on FDA review of second plant as cancer drug rollout lags expectationsCelcuity has announced that it is awaiting the U.S. Food and Drug Administration’s review of a second manufacturing facility needed for its newly approved cancer therapy. The company explained tha…
- Experts suggest new safety framework to boost predictability of CNS toxicity assessmentsA recent paper outlines a safety framework intended to make central nervous system (CNS) toxicity predictions more reliable during drug development. The authors argue that new approach methodologi…